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Running title 
Polymer-conjugated zanamivir in mice and ferrets 
ABSTRACT 
Purpose Previously, polymer-attached zanamivir had been found to inhibit influenza A 
viruses in vitro far better than small-molecule zanamivir itself.  The aim of this study was to 
identify in vitro – using the plaque reduction assay - a highly potent zanamivir-polymer 
conjugate, and subsequently test its antiviral efficacy in vivo. 
Methods By examining the structure-activity relationship of zanamivir-polymer conjugates 
in the plaque assay, we have determined that the most potent inhibitor against several 
representative influenza virus strains has a neutral high-molecular-weight backbone and a short 
alkyl linker.  We have examined this optimal polymeric inhibitor for efficacy and 
immunogenicity in the mouse and ferret models of infection. 
Results Zanamivir attached to poly-L-glutamine is an effective therapeutic for established 
influenza infection in ferrets, reducing viral titers up to 30-fold for 6 days.  There is also up to a 
190-fold reduction in viral load when the drug is used as a combined prophylactic/therapeutic in 
mice.  Additionally, we see no evidence that the drug conjugate stimulates an immune response 
in mice upon repeat administration. 
Conclusions Zanamivir attached to a neutral high-molecular-weight backbone through a short 
alkyl linker drastically reduced both in vitro and in vivo titers compared to those observed with 
zanamivir itself.  Thus further development of this polymeric zanamivir for the mitigation of 
influenza infection seems warranted. 
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INTRODUCTION 
Influenza is a persistent and constantly evolving threat to global human health.  Despite 
annual vaccinations, hundreds of millions of people are infected and hundreds of thousands die 
from the infection each year (1,2).  Prophylactic seasonal immunization against viral 
hemagglutinin antigens relies on accurate prediction of future circulating strains.  Broader-
spectrum small molecule inhibitors targeting minor surface antigens are currently approved for 
prophylactic and/or therapeutic administration.  The utility of these two M2 ion-channel 
inhibitors and two neuraminidase inhibitors - Tamiflu (oseltamivir) and Relenza (zanamivir) - 
continues to diminish due to viral mutations (3,4). In fact, since 2006 the U.S. Food and Drug 
Administration (FDA) has advised physicians not to prescribe the M2 ion-channel inhibitors 
because most circulating influenza viruses have acquired resistance to them (5).  Although the 
search for new small-molecule inhibitors is ongoing (5-8), identifying compounds with high 
potency (ideally low-nM inhibitory concentrations) has been only moderately successful.   
One promising avenue has been the chemical modification of zanamivir (1) itself.  
Specifically, its 7-O-alkyl-ether derivatives were tested in cell-based assays for inhibition of 
influenza virus infection (9-11).  The most efficacious of these analogues were conjugated to a 
polymeric scaffold and exhibited enhanced antiviral action compared to small-molecule 1-based 
parent compounds (9,10).  However, few studies have examined the structure-activity 
relationship (SAR) for 1-derivatized polymeric inhibitors in in vitro antiviral assays or, more 
importantly, their antiviral activity in vivo.  
Previously, we have identified conjugate 5a – poly-L-glutamine containing 10 mol-
percent of a 1’s 7-O-alkyl-carbamate analog 2 (Figure 1) – as a drug candidate that fills two 
unmet needs: it (i) is a potent inhibitor of drug-resistant strains of influenza viruses (12) and (ii) 
has two modes of action inhibiting both neuraminidase activity and fusion of endosomes with the 
virus (13). In the present work, we have pursued in vitro SAR studies of polymer conjugates of 1 
to identify the most efficacious candidate; the latter has been subsequently examined in vivo in 
the mouse and ferret models of influenza infection.  
 
MATERIALS AND METHODS 
Reagents  
Poly-L-glutamic acid Na salt (MW 50-100 kDa) and all other chemicals, biochemicals, 
and solvents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) unless 
otherwise noted and used without further purification. 
 
Synthesis and characterization  
Drug 1 was obtained from BioDuro (Beijing, China).  Small molecule 2, poly-L-
glutamine (5), and 5-attached 1 (5a and 5d) were synthesized by us as described previously 
(12,14,15). 
3-Acetamido-2-(1-(((2-(2-aminoethoxy)ethyl)carbamoyl)oxy)-2,3-dihydroxypropyl)-4-
guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid (3) was synthesized using a modified 
literature procedure (14,15) with tert-butyl-(2-(2-aminoethoxy)ethyl)carbamate (ChemPep, 
Wellington, FL) to introduce the linking group. Subsequent reduction/deprotection with triphenyl 
phospine/triethylamine/H2O and guanidinylation with N,N’-bis-tert-butoxycarbonyl-1H-
pyrazole-1-carboxamidine of intermediates were performed as previously described (14,15) with 
modification to the purification schemes.  For both intermediates, purification was done using a 
reverse-phase silica plug (Sep Pak C18 cartridge vac 6cc, Waters, Milford, MA).  Crude 
intermediates were loaded in water and 1:4 (v/v) water:methanol, respectively.  Product was 
eluted with 12 mL of water followed by either 15% acetonitrile or 40% methanol, respectively.  
BOC-deprotection was performed as previously described (14,15) to give compound 3. 1H NMR 
(D2O) δ (500 MHz) – 1.85 (3H, s, CH3CONH), 3.05-3.25 (4H, m, -NHCH2CH2OCH2CH2NH2), 
3.40 (1H, dd, H-9a), 3.50 (2H, m, -NHCH2CH2OCH2CH2NH2), 3.60 (1H, d, H-9b), 3.65 (2H, m, 
-NHCH2CH2OCH2CH2NH2), 3.95 (1H, m, H-8), 4.05 (1H, t, H-5), 4.35 (1H, d, H-4), 4.45 (1H, 
d, H-6), 4.90 (1H, d, H-7), 5.95 (1H, d, H-3). 
3-Acetamido-2-(1-(((4-(aminomethyl)phenyl)carbamoyl)oxy)-2,3-dihydroxypropyl)-4-
guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid (4) was synthesized analogously to 3 above 
using tert-butyl-4-aminobenzylcarbamate to introduce the linker group. 1H NMR (D2O) δ (500 
MHz) – 1.85 (3H, s, CH3CONH), 3.45 (1H, q, H-9a), 3.60 (1H, d, H-9b), 4.10-4.20 (2H, m, H-5 
and H-8), 4.35-4.45 (3H, m, PhCH2NH2 and H-4), 4.50 (1H, d, H-6), 5.0 (1H, d, H-7), 5.85 (1H, 
d, H-3), 7.25-7.35 (4H, m, aromatic).  
Polymer conjugates 5b and 5c were synthesized analogously to 5a (9), with subsitution 
of 3 or 4, respectively, for small molecule 2. Briefly, 12 mole percent of 3 or 4 were added to 
hydroxybenzotriazole-activated poly-L-glutamic acid.  After addition of catalytic pyridine, the 
reaction was stirred at room temperature for 24 h and quenched with aqueous NH4OH for an 
additional 24 h.  The reactions were then diluted with distilled water and buffer exchanged into 
the same at least four times before lyophilization. 1H NMR (D2O) δ (500 MHz) – For 5b: 1.8-2.1 
(5H, m, 2H polymer and CH3CONH), 2.1-2.4 (2H, d, 2H polymer), 3.0-3.2 (4H, m, 
NHCH2CH2OCH2CH2NH2), 3.35-3.45 (2H, m, NHCH2CH2OCH2CH2NH2), 3.45 (1H, dd, H-9b), 
3.55 (1H, d, H-9a), 3.6 (2H, m, NHCH2CH2OCH2CH2NH2), 3.95 (1H, m, H-8), 4.05-4.25 (2H, s, 
1H polymer and H-5), 4.45 (1H, d, H-4), 4.55 (1H, d, H-6), 5.7 (1H, s, H-3).  For 5c: 1.9-2.1 
(5H, m, 2H polymer and CH3CONH), 2.2-2.4 (2H, d, 2H polymer), 3.5 (1H, q, H-9a), 3.6 (1H, 
dd, H-9b), 4.1-4.35 (9H, m, 4H polymer, H-4, H-5, H-8, PhCH2NH2), 4.5 (1H, d, H-6), 5.7 (1H, 
d, H-3), 7.3 (4H, m, 4H aromatic) 
Conjugate 6a and scaffold 6. Conjugate 6a was synthesized analogously to 5a (9,12) 
using 3 mL of 0.1 M NaOH to quench the polymer conjugation reaction for 48 h at RT.  
Underivatized 6 was synthesized by quenching benzotriazole-activated poly-L-glutamate with an 
excess of 0.1 M NaOH.  After quenching, both reactions were diluted with distilled water and 
buffer-exchanged into the same at least four times using an Amicon Ultra Centrifugal Filter with 
an Ultracel regenerated cellulose membrane (15 mL, 15 kDa MW cutoff) at 4,000 x g before 
lyophilization. 1H NMR (D2O) δ (500 MHz) – For 6a: 1.1-1.4 (8H, m, -NHCH2(CH2)4CH2NH2), 
1.7-2.4 (7H, m, 4H polymer and CH3CONH), 2.8-3.05 (4H, m, -NHCH2(CH2)4CH2NH2), 3.5 
(1H, dd, H-9b), 3.6 (1H, d, H-9a), 3.8 (2H, m, H-5, H-8), 4.1-4.25 (1H, s, 1H polymer), 4.45 (1H, 
d, ZA), 4.55 (1H, d, H-6), 5.0 (1H, d, H-7), 5.75 (1H, s, H-3).  For 6: 1.7-2.3 (4H, m, 4H 
polymer), 4.2 (1H, s, 1H polymer).  
Conjugate 7a and scaffold 7.  Attachment of 2 to the activated polymer scaffold was 
performed analogously to 5a (9,12).  After 4 h, the reaction was cooled on an ice bath.  Solid N-
ethyl-N’-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.72 mg, 0.0142 mmol, 1.2 eq) 
was added to the reaction mixture, which was subsequently purged with argon gas.  A solution of 
4-dimethylaminopyridine (0.072 mg, 0.00059 mmol, 0.05 eq) in DMF (15 µL) was then added, 
and the mixture was stirred for 5 min.  A pre-cooled solution of choline chloride (6.59 mg, 
0.0472 mmol, 4 eq) in formamide (240 µL to give its final concentration in the reaction mixture 
of 30% (v/v)) was then added dropwise.  The reaction mixture was stirred on ice for 16 h and 
allowed to warm to RT overnight.  Bare 7 was synthesized by directly quenching benzotriazole-
activated poly-L-glutamate with choline chloride in formamide as described above.  After 
quenching, both reaction mixtures were diluted with distilled water and buffer-exchanged into 
the same at least four times using an Amicon Ultra Centrifugal Filter with a regenerated cellulose 
membrane (15 mL, 15 kDa MW cutoff) at 4,000 x g before lyophilization. 1H NMR (D2O) δ 
(500 MHz) – For 7a: 1.2-1.5 (8H, m, -NHCH2(CH2)4CH2NH2), 2.0-2.8 (7H, m, 4H polymer and 
CH3CONH), 2.9-3.05 (4H, m, -NHCH2(CH2)4CH2NH2), 3.2 (9H, s, -N(CH3)3), 3.5 (1H, dd, H-
9a), 3.55 (1H, d, H-9b), 3.7 (2H, s, -CH2N-) 4.05 (2H, m, H-8 and H-5), 4.1-4.3 (2H, 1H polymer 
and H-4), 4.5 (1H, d, H-6), 4.55 (2H, s, -CH2O-), 5.65 (1H, s, H-3).  For 7: 2.0-2.8 (4H, m, 4H 
polymer), 3.25 (9H, s, -N(CH3)3), 3.8 (2H, s, -CH2N-), 4.15-4.4 (1H, s, 1H polymer), 4.65 (2H, s, 
CH2O-). 
 
Plaque reduction assay 
The plaque reduction assay to determine inhibitory constants of small-molecule and 
polymeric inhibitors was performed as previously described (12).  Briefly, virus dilutions in PBS 
were incubated with an equal volume of inhibitor dilutions in PBS (serially 10-fold diluted) for 1 
h at room temperature.  Confluent MDCK cell monolayers were incubated at room temperature 
for 1 h.  The inoculum was removed by aspiration and the cells overlaid with agar medium.  
Plaques were counted after 3 and 4 days of incubation at 37°C. 
 
Influenza viruses 
Plaque-purified influenza A/WSN/33 (WSN; H1N1) was cultured in E4HG medium from 
MDCK cells (ATCC; Manassas, VA), clarified, and filtered through a 0.2-µm filter to remove 
aggregates.  Influenza virus strains A/Wuhan/359/95 (Wuhan; H3N2), A/turkey/MN/833/80 
(TKY; H4N2), and A/turkey/MN/833/80/E119D drug-resistant mutant (TKY E119D) were 
obtained from the Centers for Disease Control and Prevention (CDC) (Atlanta, GA) and 
propagated as previously described (14).  Sucrose-gradient purified influenza A/PR/8/34 (PR8; 
H1N1) was obtained from Charles River Laboratories in HEPES-saline buffer (Wilmington, 
MA) and diluted with PBS (pH 7.2) before use.  Titers were determined by serial titration in the 
plaque assay (12).  Stocks of influenza A/Nanchang/933/95 (Nanchang) H3N2 virus were grown 
in the allantoic cavities of 10-day-old embryonated hens’ eggs at 34°C for 48-72 h.  Pooled 
allantoic fluid was clarified by centrifugation and stored at -70°C. Fifty percent egg infectious 
dose (EID50) titers were determined by serial titration of virus in eggs and calculated by the 
method of Reed and Muench (16). 
 
Ethics statement 
All mice were housed at the Animal Facility of the Massachusetts Institute of Technology 
(MIT), and all studies with them were performed in accordance with the institutional guidelines. 
All mouse procedures were approved by the MIT Committee on Animal Care under protocol 
#0310-027-13. The ferret study was carried out in strict accordance with recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All ferret 
procedures were approved by the CDC Institutional Animal Care and Use Committee (IACUC) 
and in a facility accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care International. Animal studies were performed in accordance with the IACUC 
guidelines under protocol #2195TUMFERC-A3: “Studies on the Pathogenesis and Transmission 
of Recombinant Influenza Viruses in Ferrets”. 
 
Mouse experiments 
Male Balb/C mice at 8 weeks (Jackson Laboratories, Bar Harbor, ME) were used in this 
study.  They were anesthetized with intraperitoneal avertin injection and dosed intranasally in 
one nostril with a 25-µL solution of PBS (vehicle control), 1, high-molecular-weight 5, or high-
molecular-weight 5a.  Within 10 min, mice were then infected with 25 µL of a virus solution in 
PBS (1,000 pfu/mouse) delivered in the same nostril.  At 6, 24, and 48 h post-infection (p.i.), 
mice were again given PBS, 1, 5, or 5a.  
Inhibitor doses were 0.028 µmol/kg for 1, an equimolar dose of 5a (0.028 µmol/kg on a 1 
basis; 0.24 µmol/kg on a monomer basis), and 11 µmol/kg 5 (40-fold molar equivalency on a 
monomer basis).  Group sizes were: PBS – 6 mice, 5 – 3 mice, 5a – 4 mice, and mock infection – 
3 mice.  For WSN-infection, 5 mice were given 1.  For PR8-infection, 6 mice were given 1.  
Animals were euthanized with CO2 at 72 h p.i.  Whole mouse lung was harvested, rinsed in ice-
cold homogenization buffer (50 mL of PBS plus 150 µL of 35% BSA and 500 µL of a solution 
of 10,000 IU/mL penicillin G and 10,000 mg/mL streptomycin (JR Scientific, Woodland, CA)), 
flash-frozen on dry ice in 1 mL of ice-cold homogenization buffer, and stored at -80°C until 
processing.  
For PR8-infected mice, lungs were homogenized using a Branson Sonifier 250 with a 1/8” 
tapered tip probe (Branson Ultrasonics, Danbury, CT).  Total RNA was extracted from 170 µL 
of clarified lung homogenate using the PureLink Viral RNA/DNA Kit (Invitrogen, Carlsbad, 
CA) according to manufacturer’s instructions.  Viral RNA was eluted in Tris-EDTA buffer (pH 
8.0) and stored at -80°C.  Quantification of viral RNA was performed using the RNA Ultrasense 
One-step qRT-PCR System (Invitrogen) according to manufacturer’s instructions after treatment 
with RNase-free DNase (Ambion, Austin, TX).  Primer and probe to detect the encoding region 
for the M1 matrix protein were used at concentrations of 1,900 nM and 754 nM, respectively, in 
a total reaction volume of 40 µL.  Sequences of influenza-specific primers and probe (IDT, 
Coralville, IA) were previously established (17).  A Roche LightCycler® instrument was used 
for real-time reverse-transcriptase PCR using the following program: 45°C for 30 min, 95°C for 
2 min, and 50 cycles of 95°C for 5 sec, 55°C for 10 sec, and 72°C for 10 sec.  All samples and a 
standard curve of serially diluted un-passaged virus were run on the same reaction plate.  Levels 
of viral RNA in lung homogenates (18) are expressed as threshold cycle (CT), determined using 
LightCycler® 480 System software v. 1.5.  To verify that any residual polymer in homogenates 
did not interfere with RNA extraction, a sample of stock virus and a sample of homogenate from 
an untreated mouse were spiked with 5 before extraction and PCR.  A standard curve of the 
spiked virus and CT value of the spiked homogenate were in agreement with that of the un-
passaged virus.  Thus, the observed CT values reflect robust purification. 
For WSN-infected mice, their lungs were homogenized using a Dounce homogenizer on 
ice.  Viral titers of WSN in clarified murine lung homogenates were determined by 12-well 
format plaque assay and expressed in pfu/mL (12,14,19).  To exclude the possibility that the 
reduced titers measured in treated groups were a result of residual 1 or 5a in lung homogenates, 
one uninfected mouse was dosed with each inhibitor.  Lung homogenates from these mice were 
mixed in equal volume with that of infected but untreated (PBS control) mice.  No significant 
difference in virus titer was observed; the reduction in titer seen with treated mice does indeed 
reflect in vivo inhibition. 
Immune response studies were performed with 8-week old male Balb/C mice.  Mice were 
divided into two groups of four, anesthetized with intraperitoneal avertin, and challenged with 40 
µL of PBS or 40 µL of 1 mg/mL high-molecular-weight 5a at 0, 6, 24, and 48 h.  After 4 weeks, 
mice were re-challenged with three administrations of 40 µL of PBS or 40 µL of 1 mg/mL 5a.  
Serum samples were collected “pre-challenge” from a tail-vein 3 weeks before initial challenge.  
“Primary challenge” and “secondary challenge” samples were collected 10 days after initial 
challenge and secondary challenge.  Serum samples were separated using BD Microtainer serum 
separator tubes (Becton Dickinson, Franklin Lakes, NJ) and stored at -80°C. 
 
ELISA 
ELISA experiments to determine total and specific immunoglobulin levels in mouse 
serum were performed according to a modified literature procedure using Costar Universal Bind 
plates (Corning, Tewksbury, MA) (13).  Antibody pairs and standards (mouse IgG, IgM, and 
IgA) and TMB substrate were used directly from Ready-Set-Go Mouse Ig kits (eBioscience, San 
Diego, CA).  For detection of 5a-, 5-, or 1-specific antibodies by ELISA, 50 µL of 0.01 mg/mL 
5a or 5, and 50 µL of 0.1 mg/mL 2 were incubated overnight at 4°C.  Capture antibodies were 
incubated according to manufacturer’s instructions.  For washing, 1% PBST (1% BSA (w/v) and 
0.05% (v/v) Tween 20 in PBS) was used.  Blocking (4 h, RT) and serum dilutions (100 µL total 
incubation volume) were performed with 2% PBST (2% BSA (w/v) and 0.05% (v/v) Tween 20 
in PBS).  After washing five times, HRP-conjugated antibody was incubated at RT for 3 h, and 
detection performed as per manufacturer’s instruction.  Serum from all experimental mice plus 
serum from an untreated but WSN-infected mouse (positive control collected at 2.5 weeks p.i.) 
were included on each plate. Sensitivity of the assay was 1.5 ng/mL for IgG, 0.7 ng/mL for IgM, 
and 0.7 ng/mL for IgA. 
 
Ferret experiments 
Adult male Fitch ferrets, five months of age (Triple F Farms, Sayre, PA), serologically 
negative by hemagglutination-inhibition assay for currently circulating influenza viruses, were 
used in this study. Six ferrets per group were anesthetized with an intramuscular injection of a 
ketamine hydrochloride (24 mg/kg)-xylazine (2 mg/kg)-atropine (0.05 mg/kg) cocktail and 
infected intranasally with Nanchang virus at 105 EID50 in a final volume of 1 mL of PBS. Ferrets 
were sedated by ketamine before intranasal delivery of 500 µL (250 µL per nostril) of 6 µmol/kg 
bodyweight of high-molecular-weight 5a in PBS; six control ferrets received vehicle (PBS) only. 
Ferrets receiving treatment with 1 were given 0.7 µmol/kg bodyweight - equimolar to the dose of 
5a on a 1-basis - in PBS administered intranasally. The animals received daily dosing of PBS, 
5a, or 1 over a period of eight days beginning 24 h p.i. Ferrets were monitored daily for changes 
in body weight and temperature, as well as clinical signs of illness.  Body temperatures were 
measured using an implantable subcutaneous temperature transponder (BioMedic Data Systems, 
Seaford, DE). Virus shedding was measured in nasal washes collected p.i. on days 2, 4, 6, and 8 
from anesthetized ferrets as previously described (20). Virus titers in nasal washes were 
determined in eggs and expressed as EID50/mL. 
 
Statistical analysis 
Unpaired two-tailed Student’s t-test was performed using Prism 6 software. 
 
RESULTS AND DISCUSSION 
Poly-L-glutamine-attached zanamivir 5a (Figure 1A) is a far more potent inhibitor of 
influenza A virus than 1 itself due to the multivalency effect (9,12).  Its structure comprises the 
neuraminidase inhibitor 1, the biodegradable linear polypeptide, and a linker group between 
them (Figure 1).  In the first phase of this work, we have pursued in vitro SAR studies of the 
linker group and the polymer backbone in 10 mole-percent polymeric conjugates. 
Masuda et al.’s SAR study of derivatives of 1 found that modification of the 7-OH group 
with alkyl ether substituents less than ten carbon atoms in length (nominally some 16 Å) had no 
negative effects on antiviral activity compared to 1 itself (9).  Subsequent conjugation of such 
derivatives to a poly-L-glutamine scaffold greatly enhanced antiviral activity (9).  Therefore, we 
first selected a linker of only six carbon atoms in length (Figure 1B, compound 2) and 
additionally examined two alternative linker structures of approximately the same 10 Å length: 
(i) a rigid hydrophobic phenyl moiety and (ii) a flexible and hydrophilic ethylene glycol moiety 
(Figure 1B, compounds 3 and 4, respectively).  
We tested these analogs of 1 in the plaque reduction assay against three distinct strains of 
influenza virus: influenza A/WSN/33 (WSN), human influenza A/Wuhan/359/95 (Wuhan), and 
avian influenza A/turkey/MN/833/80 (TKY).  For all three strains, IC50 (half of maximal 
inhibitory concentration) values showed that 2 was the most potent inhibitor by up to 6-fold over 
flexible hydrophilic analog 3 and 50-fold over rigid analog 4 (Table I).  When attached to the 
poly-L-glutamine backbone, compound 5a – the polymeric conjugate of 2 (Figure 1D) – was at 
least as good as either 5b or 5c against Wuhan, but not necessarily WSN virus, and 
approximately 10-fold more potent against TKY virus (Table I). Thus, we selected analog 2, 
which is flexible and moderately hydrophobic, for subsequent SAR studies of the polymeric 
conjugates.  
Next, we examined the effect of the length and charge of the polymeric backbone on 
antiviral activity.  Specifically, poly-L-glutamate of either 3-15 kDa (~20-100 repeating units) or 
50-100 kDa (~330-660 repeating units) was used as a scaffold to which 10 mole-percent of 2 was 
then conjugated.  Subsequently, the glutamate side chains were modified with ammonia or 
choline groups to impart a neutral or zwitter-ionic charge state, respectively (Fig. 1E).  We 
assessed the inhibitory potency of these six polymeric conjugates in the plaque assay with 
Wuhan, wild-type TKY, and 1-resistant (E119D) TKY influenza strains.  Conjugate 7a, 
regardless of molecular weight or viral strain, had the highest IC50 value (Figure 2).  For 
negatively charged conjugate 6a, the low-molecular-weight inhibitor had an IC50 of up to 4-fold 
lower than the high-molecular-weight conjugate against all three viruses.  Conversely, high-
molecular-weight 5a was up to 15-fold more potent than the low-molecular-weight variant and 
up to 75-fold more potent compared to the corresponding charged analogs 6a and 7a. 
In their study of sialic-acid-derivatized polyacrylamides that bind the hemagglutinin of 
influenza virus, the Whitesides group reported that addition of a charge – whether positive or 
negative – to the backbone decreased binding in an erythrocyte sedimentation assay (21,22).  Our 
results herein suggest that the same trend applies to neuraminidase-binding poly-L-glutamate-
based conjugates of 2 in the plaque reduction assay.  Overall, conjugate 5a with its long neutral 
backbone and short flexible linker is the most potent inhibitor of the derivatives examined herein 
in vitro. 
In the second (in vivo) phase of this study, we tested high-molecular-weight 5a in a 
mouse model of influenza virus infection using two strains of influenza virus: WSN and 
A/PR/8/34 (PR8).  Mice were given doses of polymeric 5a, small-molecule 1, or PBS (as a 
control) intranasally, immediately followed by intranasal infection.  At 6, 24, and 48 h post-
infection (p.i.), the mice were again given 5a, 1, or PBS intranasally (Figure 3A).  Viral load was 
measured in lung homogenates at 72 h p.i.  
We determined viral titers from lung homogenates of WSN-infected mice using the 
plaque assay.  Untreated mice had high titers of 107 pfu/mL (Figure 3B).  When treated with 1, 
the titers dropped 20-fold.  Upon treatment with a molar equivalency (in terms of 1) of polymeric 
conjugate 5a, the titers plummeted 190-fold, whereas no decrease was detected from treatment 
with poly-L-glutamine (5) alone. Thus 5a is some 10-fold more potent than 1 at inhibiting WSN 
infection in mice. 
For mice infected with PR8, we analyzed lung homogenates using qRT-PCR.  Here, 
treatment with 5a reduced viral load 11-fold more than that with 1 (Figure 3C), which correlated 
well with the above-referenced WSN study.  Across all influenza strains and analytical methods, 
therefore, we observed the same trend: polymeric conjugate 5a was an order of magnitude more 
potent than small-molecule 1. 
In mice, intranasal p.i. delivery of fluids  with influenza virus – as in this study – had 
been shown to exacerbate the disease (23).  This fact could render experimental compounds less 
potent because they must inhibit significantly higher viral titers than presumed (23).  
Consequently, our data may even underestimate the potency of polymeric inhibitor 5a in the 
mouse model. 
Next, we determined the efficacy of high-molecular-weight 5a in ferrets because this 
animal model of influenza infection accurately reflects virus infectivity and antiviral activities in 
humans (24,25).  On day 0, ferrets were infected with A/Nanchang/933/95 (Nanchang) virus, a 
clinically relevant human influenza strain.  Beginning one day p.i., the ferrets were dosed daily 
with 5a, 1, or PBS (as a control).  A nasal wash was collected from each ferret on days 2, 4, 6, 
and 8 to measure viral titer.  On day 2 p.i., the ferrets given equimolar doses of 1 or 5a (in terms 
of 1) exhibited similar reductions in titer of 38- and 30-fold, respectively, compared to the PBS-
treated group.  Treatment with 5a continued to reduce viral titers significantly compared to PBS 
controls – 30- and 20-fold on days 4 and 6 p.i., respectively, – whereas treatment with 1 did not.  
Thus, polymeric conjugate 5a is a more effective therapeutic agent than 1 in this highly relevant 
ferret model of influenza infection. 
Finally, we examined whether repeated dosing with high-molecular-weight 5a induced 
immune responses, which could render 5a ineffective.  Although small molecules, such as 2, do 
not typically elicit an antibody response, as part of a polymeric conjugate they can behave as 
haptens and become immunogenic (26-28).  To assess this possibility, we challenged mice 
intranasally for four days with a daily dose of PBS (as a control) or 40 µg of 5a (which was 40 
fold higher than what was used to inhibit virus infection in mice). Ten days after the first 
administration serum samples were collected.  To increase the probability of antibody induction, 
after four weeks the mice were re-challenged for three days with PBS or 40 µg of 5a daily, and 
sera were again collected ten days later.  Using 2, 5, and 5a as capture antigens in an ELISA 
assay, we tested for the presence of specific IgG, IgM, and IgA in the serum samples. Only a 
background level of immunoglobulin was detected in the mice given 5a before, after primary, 
and after secondary challenge, the same as in control mice given PBS (Table II). Even when 5d 
with 20 mol-percent 2 was used as a capture antigen, only background levels of immunoglobulin 
were detected in 5a-treated mice, as in PBS-treated mice. Thus, upon repeated challenge with a 
dose 40-fold higher than that used in the aforementioned infection studies, no neutralizing 
antibodies against 5a or any of its components were observed. 
 
CONCLUSION 
In summary, in this study we have demonstrated that optimized polymeric drug species 
5a is an efficacious inhibitor of influenza infections in the respiratory tracts, reducing viral titers 
up to 190-fold in vivo and without stimulating an immune response.  These results coupled with 
other beneficial properties of 5a, namely, multiple modes of inhibition (13) and efficacy against 
drug-resistant virus strains (12), make it a promising inhibitor of influenza infection for further 
development. 
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LEGENDS TO FIGURES 
 
Figure 1.  Chemical structures (A) of zanamivir itself (1) and (B) of its derivatives with different 
linkers (2-4) for attachment to (C) polymer scaffolds with different electrostatic charges (neutral, 
negative, and zwitter-ionic) (5-7) to give polymer conjugates with (D) varying linker groups (5a-
5c) and (E) charges on the polymer backbone (5a-7a). 
 
Figure 2. IC50 values for low-molecular-weight (3-15 kDa; black bars) and high-molecular-
weight (50-100 kDa; white bars) conjugates 5a-7a against (A) Wuhan, (B) TKY, and (C) TKY 
E119D isolates of influenza A virus. IC50 values, reported as nanomolar concentrations of 1, 
were determined using the plaque reduction assay after pre-incubation of virus and polymer.  
Thus, IC50 values reflect inhibition of infection.  Since IC50 values of bare backbones 5-7 ranged 
from 2 to 39 mM, compared to at least 85 µM for drug conjugates, the polymers themselves had 
no appreciable antiviral activity. The IC50 values for high-molecular-weight 5a (50-100 kDa) 
against Wuhan, TKY, and TKY E119D isolates, previously reported by us (11), are included 
herein for comparison purposes.  * p < 0.05, ** p < 0.01, and *** p < 0.001 were determined by 
a two-tailed Student’s t-test.  All reported values are the mean ± SD of at least three independent 
measurements.   
 
Figure 3. (A) Experimental design to determine the efficacy of 5 and 5a in mice.  (B) Viral titers 
(pfu/mL) from plaque assay of lung homogenates from mice infected with the WSN strain.  
Equimolar doses of 1 and 5a were used; a 40-fold higher dose of backbone 5 was included as a 
control.  The PBS group was infected and given vehicle only.  Mice were dosed intranasally, 
immediately infected intranasally, and dosed again at 6, 24, and 48 h p.i.; their lungs were 
harvested 72 h p.i.  Mock-infected group, not shown here due to scale, exhibited no plaques.  (C) 
Viral load in lung homogenates of mice infected with PR8 strain.  CT values (higher numbers 
reflect lower relative levels of viral RNA expression) from qRT-PCR of lung homogenates.  The 
mock group was given only the vehicle.  Experimental design was the same as in part (B).  * p < 
0.05 and ** p < 0.01 were determined by two-tailed Student’s t-test.  All reported values are the 
mean of at least three independent measurements.   
 
Figure 4. (A) Experimental design to determine therapeutic efficacy of 5a in ferrets.  (B) Viral 
titers in nasal washings of ferrets infected with Nanchang strain of influenza virus.  Groups were 
treated with vehicle (PBS; black bars; n=6), or equimolar doses of 1 (grey bars, n=6) or 5a 
(white bars, n=6). Statistically significant differences between PBS control and treated groups 
are represented by * p < 0.05 and ** p < 0.01 as determined by two-tailed Student’s t-test.  Mean 
values ± SEM represent triplicate measurements.  
 
 
 
 
Table I.  Antiviral activities of 1’s analogs 2-4 and their polymer-attached derivatives 5a-5c 
against three strains of influenza A virus, as determined by the plaque reduction assay. 
 
Inhibitor 
IC50 (nM 1)a 
WSN  Wuhanb TKYb 
2 (1.0 ± 0.4) x 104 (4.3 ± 0.20) x 105 (4.3 ± 1.1) x 104 
3 (5.7 ± 3.9) x 104 (1.3 ± 0.56) x 106 (1.4 ± 0.34) x 106 
4 (7.6 ± 1.3) x 104 (8.4 ± 1.3) x 105 (2.3 ± 0.71) x 106 
5a (1.8 ± 0.5) x 102 21 ± 7.3 (1.8 ± 0.20) x 102 
5b (1.3 ± 0.80) x 102 (1.5 ± 0.63) x 102 (1.5 ± 0.70) x 103 
5c 81 ± 1.0 43 ± 23 (9.8 ± 1.2) x 103 
a Reported values were determined from experiments run at least in triplicate. The IC50 values (± 
SD) are expressed as nanomolar concentrations of 1, whether free or conjugated to poly-L-
glutamine. To determine the IC50 values, inhibitor and influenza viruses were incubated together 
prior to the plaque assay. Therefore, the IC50 values reflect inhibition of infection. The IC50 
values for unmodified poly-L-glutamine ranged from 2 to 14 mM (on a monomer basis), 
indicating that the polymer itself had no appreciable antiviral activity. 
b The IC50 values for compounds 2 and 5a against Wuhan and TKY strains, previously reported 
by us (12), are included here for comparison. 
 
Table II. Drug-specific serum immunoglobulin ELISA titers from mice treated with high-dose 
5a or PBS (as a control) were measured pre-challenge (“Pre-“), 10 days after primary challenge 
(“Primary”), and 10 days after secondary challenge (“Secondary”).  
 
Capture 
antigen 
Time point 
(relative to 
challenges) 
Reciprocal specific antibody titersa 
IgG IgM IgA 
PBS 5a PBS 5a PBS 5a 
1 
Pre- <20 <20 <20 <20 <20 <20 
Primary <20 <20 <20 <20 <20 <20 
Secondary <20 <20 20 20 <20 <20 
        
5 
Pre- <20 <20 20 20 20 20 
Primary <20 <20 20 20 20 20 
Secondary <20 <20 20 20 20 20 
        
5a 
Pre- <20 <20 <20 <20 <20 <20 
Primary <20 <20 20 <20 20 <20 
Secondary <20 <20 20 20 20 20 
        
5b 
Pre- <20 <20 40 40 20 20 
Primary <20 <20 40 20 20 20 
Secondary <20 <20 40 40 20 20 
        
a The titers are reported as the reciprocal of the least dilute sample with signal 2-fold above background and 
are the average of at least two measurements of each sample within each group (n=3).  Serum dilutions were 
1:20, 1:40, and 1:100. 
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